Manufacturing Milestone Masks a Pre-Efficacy Asset: Psilocybin's HTA Gauntlet Lies Ahead

Optimi Health Completes Psilocybin Production for MDD Trial & TRD Supply

Optimi Health Corp. has successfully completed and quality-released a cGMP production batch of 5mg naturally derived psilocybin capsules from its Princeton, British Columbia facility. This single batch is designated to supply both the Company's Health Canada-approved Phase 2 clinical trial for major depressive disorder (MDD) in Canada, which aims to enroll up to 200 participants with dosing expected by late 2027, and its commercial customers in Australia, where the capsules are prescribed for treatment-resistant depression (TRD) under the TGA's Authorised Prescriber Scheme.

• Integrated Production for Dual Supply: Optimi Health has achieved a significant milestone by manufacturing a single cGMP batch of 5mg psilocybin capsules that will serve two distinct purposes: supplying its Canadian Phase 2 MDD clinical trial and fulfilling commercial demand for TRD in Australia. This in-house production under a Health Canada Drug Establishment Licence ensures consistent formulation for both clinical and commercial applications.
• Advancing Clinical Research in MDD: The completed psilocybin batch is crucial for Optimi's Health Canada-authorized Phase 2 clinical trial, an open-label, multisite study designed to evaluate psilocybin-assisted therapy for major depressive disorder. The trial plans to enroll up to 200 participants, with patient dosing anticipated to conclude by the end of 2027, aiming to build an evidentiary base for future regulatory registrations.
• Expanding Commercial Access in Australia: Since 2025, Optimi has been supplying 5mg psilocybin capsules commercially to licensed clinics in Australia for treatment-resistant depression, where they are prescribed under the Therapeutic Goods Administration's Authorised Prescriber Scheme. The product is reimbursed by various public and private payers, and over 750 clinicians have been trained, with no serious adverse events reported to date.

Optimi's Phase 2 Trial Design for Major Depressive Disorder

Several recent trials in major depressive disorder (MDD) have employed rigorous randomized, controlled designs to evaluate both established and investigational treatments across a range of efficacy endpoints. The studies vary in duration, dosing strategy, and comparator selection, reflecting the breadth of therapeutic approaches under investigation.

• Anyu Peibo Capsules (Phase IIb, 2023): A 6-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose trial enrolling 172 adults with MDD (1:1 randomization; 86 per arm). The primary endpoint was change in Montgomery Åsberg Depression Rating Scale (MADRS) total score from baseline to week 6, analyzed by ANCOVA. Secondary endpoints included clinical response and remission rates per MADRS and HAMD-17, change in HAMD-17, Clinical Global Impression – Severity, Clinical Global Impression – Improvement, and Hamilton Anxiety Scale scores from baseline to week 6.

• Scopolamine Hydrobromide (2020): A randomized, double-blind, active placebo-controlled, parallel-groups, dose-response trial administering single intravenous infusions of scopolamine at three doses (4, 5, and 6 μg/kg) alongside a glycopyrronium bromide 4 μg/kg active placebo group, in 40 participants with MDD in a 1:1:1:2 ratio. The primary outcome was the MADRS, administered at baseline, 4 hours, 1 day, 3 days, 1 week, 2 weeks, 4 weeks, and 6 weeks post-infusion. Secondary measures included the Quick Inventory of Depressive Symptomatology, electroencephalography, blood samples, and Bowdle visual acuity scales recorded at baseline and at 5, 10, 15, 20, 30, 60, 120, and 240 minutes post-infusion.

• Escitalopram vs. Paroxetine (2009): A post-hoc pooled analysis of two 6-month randomized controlled trials comparing escitalopram (10 to 20 mg/day; n=394) with paroxetine (20 to 40 mg/day; n=383) in patients with MDD. The primary endpoint was mean change in MADRS total score; secondary endpoints included Clinical Global Impression – Severity and Clinical Global Impression – Improvement scores.

• Remission from Depression Questionnaire – Observational Study (2017): A prospective, multicenter, observational study in 613 MDD patients in symptomatic remission at baseline (HAMD-17 ≤7), with 6-month follow-up. The primary association evaluated was between baseline Remission from Depression Questionnaire (RDQ) score and symptomatic remission status at month 6 (HAMD-17). Secondary endpoints included relapse, composite remission status, healthcare resource utilization, quality of life, and functional impairment assessed via the Sheehan Disability Scale and Social and Occupational Functioning Assessment Scale.

Psilocybin's Therapeutic Potential Beyond Major Depressive Disorder

Psilocybin's clinical investigation is expanding beyond major depressive disorder into distinct patient populations with significant unmet need. Two active trial programmes illustrate the breadth of indications under evaluation, each employing structured psychotherapy-integrated intervention models.

• Cancer-related anxiety and depression (metastatic cancer): A Phase 1 single-arm study evaluated a second experience of Group Retreat Psilocybin Therapy in partial responders from a prior Phase 1/2 study. The intervention was delivered in a group retreat format with four primary facilitators and comprised three preparation sessions, a single psilocybin dosing day, and four integration sessions. The initial dose was 35 mg, with an optional 10 mg booster available to participants reporting low subjective effect at 60–90 minutes who passed a safety check. Pre-retreat antidepressant tapering was not required. Across 13 participants, mean Hospital Anxiety and Depression Scale (HADS) Total scores decreased from 15.08 (SD 4.35) at baseline to 9.00 (SD 4.62) at Day +8, with 69% achieving HADS scores below the clinical threshold; improvements were maintained through 24-week follow-up (mean 10.42, SD 6.93). The proportion of participants achieving a "complete" mystical experience (Mystical Experience Questionnaire ≥ 60%) increased from 38% in the first experience to 77% in the second, without an increase in challenging experiences.

• Prolonged grief disorder (PGD) in cancer-related bereavement: The PARTING trial (Psilocybin-Assisted suppoRtive psychoTherapy IN the treatment of prolonged Grief) is an open-label pilot trial targeting approximately 15 participants with cancer-related PGD. Over a 5-week intervention period, participants undergo three preparation sessions before receiving a single psychoactive dose of psilocybin (25 mg) alongside non-directive supportive guidance, followed by four integration sessions. All sessions are delivered by a psychologist and either a nurse or Indigenous Therapist. Outcomes — including grief severity, depression, anxiety, grief avoidance, psychological flexibility, connectedness, and quality of life — are assessed over a 12-month follow-up period. The trial also incorporates an artificial intelligence-assisted tool to create an artwork of each participant's psychedelic experience.

• Shared design features across non-MDD indications: Both programmes embed psilocybin administration within structured psychotherapeutic frameworks that include dedicated preparation and integration phases, reflecting a consistent model in which the pharmacological intervention is positioned within a broader therapeutic container. The group retreat model in the cancer anxiety/depression study additionally addresses scalability and equitable access — recognised barriers to population-level deployment of psychedelic therapies — by moving away from resource-intensive individual treatment formats.

Addressing Unmet Needs in Major Depressive Disorder Treatment

Despite decades of pharmacological development, treatment of Major Depressive Disorder (MDD) remains constrained by fundamental limitations in efficacy, tolerability, and treatment selection. These challenges drive significant unmet need across both first-line and subsequent lines of therapy.

• Trial-and-error treatment selection: Antidepressant prescribing remains largely empirical. In a cohort of 73,601 patients, machine learning-based selection among three SSRIs (Citalopram, Fluoxetine, Sertraline) yielded only a small improvement over current clinical practice, with treatment outcome prediction driven predominantly by baseline PHQ-9 score (AUC 0.61 as a sole predictor), underscoring the absence of robust, clinically actionable biomarkers for individualized drug selection.

• High rates of treatment resistance: Approximately 30% of patients treated for MDD develop treatment-resistant depression (TRD). The STAR*D study demonstrated that remission rates decline progressively with each antidepressant failure — 37%, 31%, 14%, and 13%, respectively — leaving a substantial patient population without adequate symptom control through conventional agents.

• Limited differentiation between next-step strategies: For patients failing initial antidepressant treatment, neither augmentation nor switching has demonstrated a clear superiority. In a propensity-score-matched analysis of STAR*D participants (N = 269 per group), likelihood of remission (risk ratio, 1.14; 95% CI, 0.82–1.58), response, time to remission (log-rank P = 0.946), and quality of life did not differ between strategies.

• Delayed onset of action and tolerability burden with standard agents: Monoaminergic antidepressants — SSRIs and SNRIs — carry delayed onset of action and are associated with adverse events that compromise adherence. For example, nausea (20.9–31.2%) and vomiting (2.9–6.5%) were the most common treatment-emergent adverse events with vortioxetine (5–20 mg/day), while sexual dysfunction and discontinuation symptoms represent class-level tolerability concerns across agents.

• Long-term safety and abuse potential of novel rapid-acting agents: While ketamine and esketamine address the gap in rapid-acting therapy for TRD, their use is complicated by dose-dependent cognitive effects — particularly on episodic and working memory — potential liver toxicity with prolonged exposure, bladder inflammation ("ketamine cystitis"), and abuse potential. Many studies indicate that ketamine's therapeutic effects may subside within weeks, necessitating repeated administrations to sustain reductions in depressive symptoms and suicidality.

• Lack of validated predictive biomarkers: Objective biomarkers capable of predicting and monitoring therapeutic response are urgently needed to enable personalized interventions and reduce patient exposure to ineffective treatments. Mass spectrometry-based multi-omics approaches are under investigation, but clinically informative biomarkers for precision psychiatry in MDD have not yet been established.

Quality Psilocybin Production Fuels Dual MDD/TRD Strategy

The successful cGMP production of naturally derived psilocybin capsules by Optimi Health Corp. represents a pivotal moment for the burgeoning field of psychedelic medicine. This achievement underscores the industry's commitment to overcoming manufacturing hurdles, ensuring that potential therapies meet the stringent quality and standardization requirements essential for widespread clinical adoption. By producing a high-quality, naturally derived product, the company is not only addressing the practical challenges of supply but also engaging with the ongoing discussion about the potential nuances between naturally sourced and synthetic compounds, an area where further human validation is needed.

The company's strategic decision to allocate this batch to both a Canadian Phase 2 trial for major depressive disorder (MDD) and commercial distribution for treatment-resistant depression (TRD) in Australia highlights a pragmatic approach to market entry. This dual pathway allows for the simultaneous generation of robust clinical evidence in a controlled trial setting while providing early access to patients with severe, unmet needs under existing regulatory frameworks. This strategy could accelerate the understanding of psilocybin's therapeutic potential across different patient populations and regulatory environments.

However, the path forward is not without its complexities. While early studies have shown promising antidepressant effects, particularly in open-label trials for bipolar II depression and severe TRD in Veterans, a recent Phase 2b randomized clinical trial for TRD did not achieve its primary endpoint, suggesting that efficacy may be more nuanced than initially perceived. Furthermore, safety considerations remain paramount; studies have reported safety signals such as increased suicidal ideation on dosing days and rare but serious adverse events like hallucinogen persisting perception disorder. The observed rise in psilocybin-related poison center encounters, even if overall numbers are low, signals a need for continued vigilance and robust public health monitoring as access expands. These factors underscore the critical importance of the ongoing Phase 2 MDD trial and the need for comprehensive data to fully establish the benefit-risk profile of psilocybin in diverse clinical settings.